Indiana-based Eli Lilly invests $20 million in Nexus facility to enhance production capabilities.

Indiana pharmaceutical giant Eli Lilly has entered into a strategic partnership with Nexus Pharmaceuticals, investing $20 million into Nexus’s Pleasant Prairie, Wisconsin, facility. This move is set to significantly expand production capacity and create more than 100 new jobs in the area.

The partnership is aimed at enhancing the Pleasant Prairie site’s ability to produce critical, life-saving medications. Eli Lilly’s investment will support upgrades and the installation of new equipment, marking a pivotal moment in the facility’s operational capabilities. “This expansion will not only increase our production capacity but also improve our ability to ensure a consistent supply of medications,” said Mariam Darsot, CEO of Nexus Pharmaceuticals.

Local officials have lauded the investment as a major economic boost. Pleasant Prairie Village President John Steinbrink emphasized the local impact, stating, “The collaboration between Eli Lilly and Nexus Pharmaceuticals is a testament to our community’s growing influence in the pharmaceutical industry and our commitment to supporting high-quality jobs.”

The investment comes at a time when the pharmaceutical industry is under increasing pressure to ensure a reliable drug supply chain amidst global disruptions. Eli Lilly’s CEO David Ricks commented on the strategic nature of the partnership, noting, “Our investment in Nexus Pharmaceuticals is part of our broader strategy to enhance the resilience of our manufacturing network.”